Neuromodulation for Lower Urinary Tract Dysfunction: Mechanisms, Modalities, and Patient Selection

Area of Science:

• Urology
• Neuroscience
• Medical Technology

Background:

• Lower urinary tract dysfunction (LUTD) encompasses various symptoms like urgency and incontinence.
• Many patients experience persistent symptoms despite conventional behavioral and pharmacologic therapies.
• Neuromodulation offers a unique approach by targeting neural pathways rather than detrusor contractility.

Purpose of the Study:

• To review the current evidence and clinical relevance of neuromodulation for treating lower urinary tract dysfunction (LUTD).
• To synthesize literature on different neuromodulation modalities, their efficacy, durability, and safety profiles.

Main Methods:

• A narrative review of PubMed/MEDLINE literature and major urological guidelines up to May 2026.
• Evidence was prioritized based on methodological rigor and synthesized qualitatively by treatment modality, patient phenotype, and outcomes.

Main Results:

• Sacral neuromodulation (SNM) demonstrates 5-year success rates of 67-82% for overactive bladder (OAB), with technological advancements improving patient experience.
• Tibial nerve stimulation, including percutaneous and implantable options, shows efficacy for OAB but requires ongoing treatment or has indirect comparisons to SNM.
• Adverse events associated with neuromodulation are generally minor and reversible.

Conclusions:

• Neuromodulation is a valuable treatment for LUTD, but patient selection and risk stratification require improvement.
• Standardized outcome measures and comparative studies are essential for optimizing neuromodulation therapies.
• Physiology-guided programming is a priority for enhancing treatment effectiveness.